What's Happening?
Corcept Therapeutics has announced that its experimental drug relacorilant, combined with chemotherapy, significantly improved overall survival in a Phase III study for platinum-resistant ovarian cancer.
The study showed a 35% reduction in the risk of death compared to chemotherapy alone, with median overall survival reaching 16 months. The drug's safety profile was comparable to the control group, with no added toxicity. The FDA has accepted Corcept's new drug application, with a decision expected by July 11.
Why It's Important?
The promising results from Corcept's Phase III trial could offer a new treatment option for patients with platinum-resistant ovarian cancer, a condition with historically limited survival gains from chemotherapy. The drug's competitive efficacy and safety profile position it as a potential challenger to existing treatments from major pharmaceutical companies like Merck and AbbVie. If approved, relacorilant could significantly impact the ovarian cancer treatment landscape, providing hope for improved patient outcomes.
